Tumor Tissue Analysis in Patients Receiving Imatinib Mesylate for Malignant Glioma

• Status: Completed
• Trial end date: 2008-11-11
• Target enrollment: 0
• Participant gender: All

Summary

RATIONALE: Collecting samples of tumor tissue and blood from patients with cancer to study in the laboratory may help doctors learn how patients respond to treatment.

PURPOSE: This clinical trial is looking at tumor tissue samples from patients receiving imatinib mesylate for malignant glioma to see how much imatinib mesylate is found in the tumor tissue.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
• Collaborator: National Cancer Institute (NCI)
• Treatments: Imatinib Mesylate

Criteria

DISEASE CHARACTERISTICS:

• Histologically confirmed malignant glioma of 1 of the following subtypes:

• Low-grade glioma

• Anaplastic astrocytoma

• Anaplastic oligodendroglioma

• Glioblastoma multiforme

• Unifocal disease that is progressive or recurrent after prior radiotherapy and/or chemotherapy

• Scheduled to undergo surgical resection

• Able to undergo maximal surgical resection of tumor mass

PATIENT CHARACTERISTICS:

• Karnofsky performance status 70-100%

• Mini Mental Status Exam ≥ 15

• Absolute neutrophil count ≥ 1,500/mm³

• Platelet count ≥ 100,000/mm³

• Creatinine ≥ 1.7 mg/dL

• BUN ≤ 2 times upper limit of normal (ULN)

• Transaminases ≤ 4 times ULN

• Not pregnant or nursing

• Fertile patients must use effective contraception during and for ≥ 1 month after completion of study treatment

• No other medical illness that would preclude study treatment, including any of the following:

• Serious infection

• Uncontrolled hypertension

• Unstable angina pectoris

• Uncontrolled cardiac dysrhythmia

PRIOR CONCURRENT THERAPY:

• See Disease Characteristics

• Recovered from all prior therapy

• At least 4 weeks since prior investigational drugs

• No more than 1 prior chemotherapy regimen

• No concurrent chemotherapy, biologic therapy, or radiotherapy

• No concurrent medications that may interact with imatinib mesylate or interfere with hepatic cytochrome P450 system